Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Company Overview

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents. In addition, ORIC-944, a potent inhibitor of discoidin domain receptors 1 and 2 (DDR1/2), is in late preclinical development for modulation of fibrotic tumor stroma and metastatic disease control. Oric applies translational biology and biomarker-driven strategies to guide patient selection and optimize therapeutic indices across its programs.

Founded in 2016 by a team of oncology R&D veterans, Oric Pharmaceuticals completed its initial public offering on the Nasdaq Global Market in March 2021 under the ticker symbol ORIC. The company has established collaborative relationships with leading academic institutions and clinical research organizations across North America and Europe to support its global clinical development plans. Its senior management team is led by President and Chief Executive Officer Johanna Mercier, Ph.D., who brings extensive experience in small molecule drug discovery and development from prior roles at major pharmaceutical companies.

Oric leverages a proprietary target discovery platform that integrates genomic, proteomic and functional screening data to uncover resistance pathways and potential combination strategies. By incorporating biomarker analyses early in development, the company aims to accelerate timelines and deliver therapies with differentiated mechanisms of action. Multiple programs are advancing through IND-enabling studies, with key clinical milestones anticipated over the coming 12 months.

Key Stats

• Today's Range: $10.74 to $12.55
• 50-Day Range: $7.50 to $12.10
• 52-Week Range: $7.23 to $14.93
• Volume: 3.61 million shs
• Average Volume: 1.57 million shs
• Market Capitalization: $1.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.27
• Consensus Rating: Moderate Buy

Oric Pharmaceuticals Stock Analysis - MarketRank™

Oric Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 644th out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 13 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Oric Pharmaceuticals has a consensus price target of $19.27, representing about 59.3% upside from its current price of $12.10.

Amount of Analyst Coverage

Oric Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oric Pharmaceuticals are expected to decrease in the coming year, from ($1.45) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oric Pharmaceuticals is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oric Pharmaceuticals is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oric Pharmaceuticals has a P/B Ratio of 3.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.59% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 13.53, which indicates bearish sentiment.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently decreased by 0.25%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oric Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oric Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.81

News Sentiment

Oric Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oric Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Oric Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 7/24/2026
• Next Earnings (Estimated): 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORIC
• CIK: 1796280
• Web: www.oricpharma.com
• Phone: 650-388-5600
• Fax: N/A
• Employees: 80
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Oric Pharmaceuticals: $19.27
• High Price Target: $25.00
• Low Price Target: $14.00
• Potential Upside/Downside: +59.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$129.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -35.33%
• Return on Assets: -33.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.33
• Quick Ratio: 16.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.90 per share
• Price / Book: 3.10

Miscellaneous

• Outstanding Shares: 103,520,000
• Free Float: 97,617,000
• Market Cap: $1.25 billion
• Optionable: Optionable
• Beta: 1.02